• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

3 Favorite Biotech Stocks for the Second Quarter

Your questions are answered in our latest addition of the biotech mailbag.
By BRET JENSEN
Mar 31, 2018 | 12:00 PM EDT
Stocks quotes in this article: NVTA, AKAO, DVAX, SGYP

It is hard to believe that it is the end of March and the first quarter is over. The end of the quarter couldn't come soon enough for investors who have been rocked by volatility over the past two months, including the worst weekly performance for equities in over two years last week. So, I think an appropriate way to end the quarter is another edition of the Biotech Mailbag.

What is wrong with biotech lately?

After sitting near 52-week highs a few weeks ago, the main biotech indices have fallen seven to eight percent over the past couple of weeks. Obviously, a good portion of this is due to the decline in the overall market as well as the increased volatility, which is rarely kind to the high-beta parts of equities such as biotech.

In addition, there has been a dearth of M&A activity in the sector over the past two months after a promising start to 2018. What's more, it appears developmental firms are recently having a tougher time or getting worse terms raising additional capital. For example, look at this week's "fire sale" secondary offering from Invitae Corp. (NVTA) .

Look for the market and the sector to start to settle down as companies start to deliver first-quarter results. I expect many to beat consensus projections reflecting the slashing of the corporate tax rate (not fully factored in yet), robust domestic and global growth and a weak dollar.

What are some of your favorite biotech stocks for the second quarter?

I continue to like Achaogen (AKAO) , whose stock has actually risen during the past few weeks of market carnage. An Ad Comm Panel for the company's lead drug candidate has been scheduled for May 2, which should result in a recommendation for approval, which the FDA should rubber stamp in late June. One beneficial owner sure believes in the investment case around this antibiotic concern, amassing a stake of nearly 15% in the last couple of quarters.

I also like Dynavax Technologies (DVAX) , which has a held up in recent weeks. This should be an inflection year for the company as it rolls out its recently approved Heplisav-B vaccine.

Dynavax is also starting to get more notice for the progression of its oncology asset SD-101, which is moving through development. This could power further gains. More data around this compound will be presented at the upcoming American Association for Cancer Research Conference, which runs from April 14 through April 18, as well as the American Society of Clinical Oncology event, or ASCO, which happens the first week of June in Chicago.

Finally, out on the risk curve is beaten down Synergy Pharmaceuticals (SGYP) . The stock has suffered as a result of poor management execution since its lead drug candidate Trulance was approved for Chronic Idiopathic Constipation in January 2017. However, Synergy recently replaced its CEO and Trulance was approved for IBS-C (irritable bowel syndrome with constipation) this January.

This approval expanded Trulance's potential customer base by one-third and the compound is also benefiting from an enlarged sales force as well new insurance coverage contracts. Scripts have recently been rising by five percent on a weekly basis.

Synergy posted solid fourth-quarter results on March 1. If it follows up with a good first-quarter report, maybe the stock can get off the schneid.

Bret Jensen is a regular contributor to Real Money Pro. Click here to learn about this dynamic market information service for active traders and to receive daily columns from Jensen, Ed Ponsi, Paul Price and others.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long AKAO, DVAX, NVTA and SGYP.

TAGS: Investing | U.S. Equity | Regulation | Markets | Healthcare | Earnings | How-to | Stocks

More from Healthcare

Trade Carefully With Soaring Gritstone Oncology

Bruce Kamich
Jan 21, 2021 8:16 AM EST

The history we are concerned about is the past couple of weeks.

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login